Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, He'nan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei Xiangya Hospital Central South University, Changsha, Hunan The Central Hospital of Yongzhou, Yongzhou, Hunan Liaoning Cancer Hospital & Institute, Shenzhen, Liaoning Xijing Hospital, Xi’an, Shanxi West China Hospital，Sichuan University, Chengdu, Sichuan The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Zhejiang cancer Hospital, Hangzhou, Zhejiang Peking Union Medical College Hospital, Beijing Peking University People's Hospital, Beijing Fudan University Shanghai Cancer Center, Shanghai Shanghai Sixth People's Hospital, Shanghai Tianjin Medical University Cancer Institute & Hospital, Tianjin